Pulmonary Fibrosis and ILD Programs

The Pulmonary Fibrosis/Interstitial Lung Disease Program treats patients with interstitial lung disease (ILD), pulmonary fibrosis (IPF), and related conditions, including collagen vascular-associated pulmonary diseases, Hermansky-Pudlak Syndrome, histiocytosis X, tuberous sclerosis, LAM, glycogen storage disease (Gaucher’s), secondary pulmonary hypertension, and advanced stage sarcoidosis and others. Patients with these conditions require specific medical attention, close follow-up, and associated services to optimize management of the disease.

There is an emerging area of new treatment options for patients with interstitial lung disease, and Mount Sinai and National Jewish Health are positioned to offer the latest and most promising therapies to patients with ILD. We provide advanced, comprehensive care for ILD and related conditions, with the goals of improving outcomes and survival, and enhancing our patients’ overall quality of life. We encourage participation in studies aimed at understanding the diseases and /or finding specific treatments.